NASDAQ:ALLK

Allakos Stock Forecast, Price & News

$93.04
+1.80 (+1.97 %)
(As of 06/24/2021 11:12 AM ET)
Add
Compare
Today's Range
$91.89
$93.40
50-Day Range
$89.26
$113.31
52-Week Range
$66.01
$157.98
Volume1,911 shs
Average Volume249,390 shs
Market Capitalization$4.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92
30 days | 90 days | 365 days | Advanced Chart
Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.


Allakos logo

About Allakos

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

594th out of 2,105 stocks

Pharmaceutical Preparations Industry

288th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Allakos (NASDAQ:ALLK) Frequently Asked Questions

Is Allakos a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Allakos stock.
View analyst ratings for Allakos
or view top-rated stocks.

What stocks does MarketBeat like better than Allakos?

Wall Street analysts have given Allakos a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allakos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Allakos
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings data on Sunday, May, 9th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.18.
View Allakos' earnings history
.

How has Allakos' stock price been impacted by COVID-19 (Coronavirus)?

Allakos' stock was trading at $58.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALLK stock has increased by 59.6% and is now trading at $93.04.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALLK?

5 brokers have issued 12-month price targets for Allakos' stock. Their forecasts range from $145.00 to $230.00. On average, they anticipate Allakos' stock price to reach $197.67 in the next twelve months. This suggests a possible upside of 112.5% from the stock's current price.
View analysts' price targets for Allakos
or view top-rated stocks among Wall Street analysts.

Who are Allakos' key executives?

Allakos' management team includes the following people:
  • Dr. Robert Alexander, CEO & Director (Age 51, Pay $1.45M)
  • Dr. Adam L. Tomasi, Pres & COO (Age 51, Pay $1.09M)
  • Mr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 58, Pay $719.87k)
  • Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 62, Pay $880.07k)
  • Mr. Baird Radford III, Chief Financial Officer
  • Dr. Ruby Casareno Ph.D., Sr. VP of Technical Operations
  • Dr. Sally D. Bolmer, Sr. VP of Regulatory Affairs & Drug Devel.
  • Mr. Tim Varacek, Chief Commercial Officer
  • Mr. Alan Chang, Director of Medical Affairs & Data Analytics

Who are some of Allakos' key competitors?

What other stocks do shareholders of Allakos own?

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.39%), Redmile Group LLC (4.52%), Capital International Investors (4.25%), Baker BROS. Advisors LP (1.31%), Janus Henderson Group PLC (1.02%) and Alliancebernstein L.P. (0.95%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander and Robert J More.
View institutional ownership trends for Allakos
.

Which major investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Redmile Group LLC, BlackRock Inc., Bank of Montreal Can, Rock Springs Capital Management LP, Cormorant Asset Management LP, Credit Suisse AG, and Baker BROS. Advisors LP. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, and Robert J More.
View insider buying and selling activity for Allakos
or view top insider-selling stocks.

Which major investors are buying Allakos stock?

ALLK stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Point72 Asset Management L.P., Jennison Associates LLC, Morgan Stanley, Voloridge Investment Management LLC, Moneta Group Investment Advisors LLC, Geode Capital Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Allakos
or or view top insider-buying stocks.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $93.04.

How much money does Allakos make?

Allakos has a market capitalization of $4.98 billion. The company earns $-153,480,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 141 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

Where are Allakos' headquarters?

Allakos is headquartered at 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]


This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.